At Plus Therapeutics, our mission is rooted in innovation, precision, and the pursuit of better outcomes for patients facing some of the most aggressive and difficult-to-treat cancers. In a recent interview with AlphaStreet, our President and CEO, Marc Hedrick, M.D., shared insight into the company’s long-term vision, clinical strategy, and what sets Plus apart in the evolving field of oncology therapeutics.
Dr. Hedrick discussed how Plus Therapeutics is leveraging proprietary radiotherapeutic platforms to address high unmet medical needs, particularly in central nervous system (CNS) cancers such as glioblastoma (GBM) and leptomeningeal metastases (LM). He also outlined the company’s clinical trial progress, regulatory milestones, and commitment to building a strong foundation for future growth.
“Our strategy is focused on delivering targeted cancer therapies directly to the tumor site, offering a more precise and potentially more effective treatment for patients with limited options,” said Dr. Hedrick.
To read the full interview and learn more about the company’s scientific and strategic direction, access the Q&A here:
Read the full interview on AlphaStreet
For additional information about our mission, pipeline, and clinical trials, visit plustherapeutics.com
#PlusTherapeutics #PSTV #CancerResearch #OncologyInnovation #Radiotherapeutics #CNSCancers #Glioblastoma #LeptomeningealMetastases #PrecisionMedicine #LeadershipInBiotech #BiotechCEO #ClinicalTrials #NeuroOncology
Recent Comments